Naval Daver, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX tells us about the latest treatments in development for patients with AML. There are a lot of new data being presented at this years’ ASH 2017 meeting in Atlanta, GA, and Naval updates us on progress with some of the key agents. Included in his summary are selinexor, sorafenib, quizartinib, gilteritinib, FLX925 and lirilumab. MD Anderson are involved in many of these studies and Naval gives us his insights into how they are overcoming the challenges of sequencing new medicines. In addition, Dr Daver talks about MD Anderson’s broad checkpoint portfolio of immune checkpoint inhibitors. This video was recorded at the ASH 2017 meeting in Atlanta, GA.